Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Stifel Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $230

Author: Benzinga Newsdesk | March 15, 2024 09:37am
Stifel analyst Annabel Samimy maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $225 to $230.

Posted In: JAZZ

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist